Calamos Advisors LLC Acquires 3,458 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Calamos Advisors LLC lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 145,800 shares of the medical research company’s stock after purchasing an additional 3,458 shares during the period. Calamos Advisors LLC’s holdings in Thermo Fisher Scientific were worth $75,850,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the stock. AMF Tjanstepension AB acquired a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth about $42,409,000. Czech National Bank boosted its position in shares of Thermo Fisher Scientific by 7.0% during the 3rd quarter. Czech National Bank now owns 77,816 shares of the medical research company’s stock worth $48,135,000 after purchasing an additional 5,076 shares during the period. GAMMA Investing LLC increased its stake in Thermo Fisher Scientific by 29.8% during the 3rd quarter. GAMMA Investing LLC now owns 4,851 shares of the medical research company’s stock worth $3,001,000 after buying an additional 1,115 shares during the period. Diversified Trust Co raised its holdings in Thermo Fisher Scientific by 7.6% in the third quarter. Diversified Trust Co now owns 10,190 shares of the medical research company’s stock valued at $6,303,000 after acquiring an additional 717 shares in the last quarter. Finally, Chemistry Wealth Management LLC grew its stake in shares of Thermo Fisher Scientific by 8.9% during the third quarter. Chemistry Wealth Management LLC now owns 587 shares of the medical research company’s stock worth $363,000 after purchasing an additional 48 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.7 %

Shares of TMO stock opened at $593.38 on Tuesday. The firm’s 50-day simple moving average is $541.37 and its 200-day simple moving average is $571.18. The firm has a market cap of $226.97 billion, a P/E ratio of 35.90, a PEG ratio of 4.06 and a beta of 0.77. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a 1-year low of $493.30 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.29 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were given a $0.39 dividend. The ex-dividend date of this dividend was Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.44%.

Thermo Fisher Scientific announced that its board has authorized a stock buyback plan on Friday, November 15th that authorizes the company to buyback $4.00 billion in shares. This buyback authorization authorizes the medical research company to buy up to 2% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on TMO. Bernstein Bank lifted their target price on shares of Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a report on Tuesday, October 22nd. Wells Fargo & Company boosted their target price on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a research report on Friday. Raymond James restated an “outperform” rating and set a $667.00 target price (up previously from $650.00) on shares of Thermo Fisher Scientific in a research report on Monday. TD Cowen lifted their price objective on Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. Finally, Evercore ISI lowered their price objective on Thermo Fisher Scientific from $630.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average price target of $658.00.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 9,000 shares of the company’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $552.86, for a total value of $4,975,740.00. Following the completion of the transaction, the chief executive officer now directly owns 14,608 shares in the company, valued at approximately $8,076,178.88. This represents a 38.12 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders sold 29,000 shares of company stock valued at $15,859,540. Corporate insiders own 0.34% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.